Arrowhead (ARWR) traded down -0.58 % during a 24 hours period ending at 10:05 PM Central Europe on Monday 26th. One Arrowhead stock can currently be bought for about USD 58.98 on popular exchanges. Current supply of Arrowhead stocks is 141.3 mn. Arrowhead has a current market capitalization of USD 8.2 bn and approximately USD 50.6 mn worth of Arrowhead was traded on exchanges in the last 24 hours. Since last month end, Arrowhead has traded -12.18 % down. Simple moving average of last 200 days is at USD 71.87. The highest price of past 52 weeks was recorded at USD 95.49 on 07/22/2026. 52 weeks low was at USD 37.06 on 11/20/2025.
Here is how related stocks have performed in the past 24 hours:
Donaldson (DCI) traded down -1.54 % and now trades at USD 85.51. Current market capitalisation for Donaldson is USD 9.8 bn. Donaldson has a current price to earnings ratio of 22.06.
Bio-rad Laboratories (BIO-B) traded down -0.25 % and now trades at USD 364.15. Bio-rad Laboratories has a market capitalisation of USD 9.7 bn.
Advanced Drainage (WMS) traded down -0.4 % and now trades at USD 131.23. Current market capitalisation for Advanced Drainage is USD 9.8 bn. Advanced Drainage has a current price to earnings ratio of 22.32.
Aurora Innovation (AUR) traded down -1.03 % and now trades at USD 4.87. Aurora Innovation has a market capitalisation of USD 9.6 bn.
Quantinuum (QNT) traded up 1.67 % and now trades at USD 37.53. Current market capitalisation for Quantinuum is USD 9.7 bn. Quantinuum Inc. has seen a modest uptick in its share price following a brief rally, though the company’s overall financial footprint remains small. The firm reported a quarterly turnover of only a few million dollars, despite a surge in revenue growth year‑over‑year. Its balance sheet holds a few hundred million in cash, a figure that underscores the company’s limited scale compared with larger quantum‑technology peers. Analysts note that Quantinuum’s recent technical milestones—particularly a reported logical fidelity of 99.9995 %—offer strong proof of concept but do not yet translate into a sizable revenue engine. The market’s valuation of the company is largely driven by speculative expectations of future quantum computing applications rather than current earnings. Consequently, investor sentiment remains cautious, with the stock reflecting a blend of technological promise and the uncertainty of commercial deployment timelines.
About Arrowhead
Arrowhead Pharmaceuticals, Inc. is a biotechnology company operating in the health care sector with its base in Pasadena, United States. The company specializes in developing medicines that target and silence genes to treat intractable diseases. Their services are available exclusively in the United States, and they are listed on the Nasdaq stock exchange. Their IPO date is June 16, 1993.